These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 32630154)

  • 1. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
    Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
    Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C
    Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
    Cimadamore A; Massari F; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Moch H
    Curr Drug Targets; 2020; 21(16):1664-1671. PubMed ID: 32208115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
    Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
    Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on immunotherapy for renal cancer.
    Canales Rojas R
    Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.